Last reviewed · How we verify
Oral palonosetron
Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting.
Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV), Prevention of postoperative nausea and vomiting (PONV).
At a glance
| Generic name | Oral palonosetron |
|---|---|
| Sponsor | Helsinn Healthcare SA |
| Drug class | 5-HT3 receptor antagonist |
| Target | 5-HT3 receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
This action is thought to be mediated through the blockade of 5-HT3 receptors on the vagus nerve terminals and in the central nervous system. By blocking these receptors, palonosetron reduces the release of serotonin, which is a key contributor to nausea and vomiting. This mechanism of action is particularly effective in preventing chemotherapy-induced nausea and vomiting.
Approved indications
- Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)
- Prevention of postoperative nausea and vomiting (PONV)
Common side effects
- Headache
- Dizziness
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Fatigue
- Injection site reaction
- Rash
- Pruritus
Key clinical trials
- An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC (PHASE4)
- AKY15-HK-301_NEPA Study (PHASE2)
- A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron (NA)
- APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer (PHASE3)
- Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer (PHASE3)
- Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk) (PHASE4)
- A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients (PHASE4)
- Cisplatin Disposition and Kidney Injury (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oral palonosetron CI brief — competitive landscape report
- Oral palonosetron updates RSS · CI watch RSS
- Helsinn Healthcare SA portfolio CI